NCT04430452View on ClinicalTrials.gov

Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Advanced Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions
BIOLOGICAL

Durvalumab

Given IV

RADIATION

Hypofractionated Radiation Therapy

Undergo hypofractionated RT

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Mary Feng, MD

OTHER